Test tag block 

Test tag block

Test tag block

Test tag block

Evolocumab

Game-changing cholesterol-buster further reduces heart attack, strokeA new outcomes study shows that the PCSK9 inhibitor Repatha significantly reduced the risk of hard major adverse cardiovascular events in high-risk patients by 20%.
Are PCSK9 inhibitors too pricey?
Are PCSK9 inhibitors too pricey?PCSK9 inhibitors such as alirocumab (Praluent, Sanofi) and evolocumab (Repatha, Amgen) are priced too high to benefit the US healthcare system, according to a new study.
PCSK9 inhibitor benefits patients with statin intolerancePCSK9 inhibitor benefits patients with statin intolerance
Watch list 2016: Top therapeutic areas
Watch list 2016: Top therapeutic areasExperts say you should follow these 6 therapeutic areas.
FDA approves major cholesterol drugThe FDA on August 27 approved Repatha (evolocumab) injection for some patients who are unable to get their low-density lipoprotein (LDL) cholesterol under control with current treatment options.
FDA advisors favor new cholesterol-lowering drugs that target PCSK9FDA advisory committee okays two monoclonal antibody formulations in two days for treatment of hypercholesterolemia.
FDA panel recommends approving Repatha, Praluent to lower cholesterolFDA’ s Endocrinologic and Metabolic Drugs Advisory Committee recommended this week to approve cholesterol-lowering drug evolocumab (Repatha) from Amgen in a 15-0 vote. It also voted 13-3 in favor of FDA approving Sanofi and Regeneron's Praluent (alirocumab), but most panel members called for a restricted label in high-risk patients with genetic conditions causing elevated cholesterol, rather than wider use in the general elevated cholesterol population.
[BLOG] Pipeline advancement responsible for upturn in global pharma R&DThe world’s leading 30 pharmaceutical companies spent a combined $112 billion on research and development (R&D) in 2013, an increase of $723 million over the previous year. According to our new Global Pharmaceutical Benchmark Report, Roche was the R&D spending leader, outlaying nearly $10 billion in 2013. Meanwhile, Novartis and Johnson & Johnson (J&J) increased their R&D spend the most between 2012 and 2013, with each adding around $500 million to their respective clinics. Novartis’ R&D spending grew by 5.6% to $9.8 billion, and J&J spent $8.2 billion, which was up by 6.8% from 2012.
[BLOG]: AHA Scientific Sessions 2014: Where do the PCSK9s fit in the post-IMPROVE-IT world? A “modest” proposalThis year, the American Heart Association (AHA) Scientific Sessions were held in Chicago, Illinois, from November 15 to 19. Of all of the late-breaking clinical trials presented at AHA 2014, the IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial) study of Merck’s low-density lipoprotein cholesterol (LDL-C)-reducing drugs—the statin, Zocor (simvastatin), and the fixed-dose combination, Vytorin (ezetimibe/simvastatin)—stole the show.
Studies: Evolocumab shows promise in reducing LDL cholesterol in patients with genetic disorders that cause high cholesterolRecent data from 2 phase 3 studies showed treatment with evolocumab, a novel investigational low-density lipoprotein cholesterol (LDL-C)-lowering medication, resulted in a statistically significant reduction in LDL-C compared to placebo in patients with different types of familial hypercholesterolemia (FH).